Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Autor: Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigators, Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.

Publikováno v: Ann Transl Med
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f1362cea0664cfe2470bd04f49b410
https://hdl.handle.net/2318/1742132

842TiP - A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)

Autor: Powles, T., Grivas, P., Aragon-Ching, J.B., Faroun, Y., Kessler, E.R., Tomita, Y., Chakrabarti, D., Laliberte, R.J., Shnaidman, M., Petrylak, D.

Publikováno v: In Annals of Oncology 1 October 2016 27 Supplement 6:vi292-vi292

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Autor: Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Robert M Rifkin, Habte Aragaw Yimer, Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Andrew Boon Ming Lim, Kenshi Suzuki, Hiroshi Kosugi, George Grigoriadis, Irit Avivi, Thierry Facon, Sundar Jagannath, Sagar Lonial, Razi Uddin Ghori, Mohammed Z H Farooqui, Patricia Marinello, Jesus San-Miguel, Andrew Lim, Trish Walker, Andrew Nicol, Donna Reece, Mohamed Elemary, Jean Samuel Boudreault Pedneault, Michel Attal, Katja Weisel, Monika Engelhardt, Andreas Mackensen, John Quinn, Amos Cohen, Hila Magen-Nativ, Noam Benyamini, Alessandra Larocca, Morio Matsumoto, Shinsuke Iida, Takayuki Ishikawa, Yukio Kondo, Kazutaka Sunami, Kiyoshi Ando, Takanori Teshima, Takaaki Chou, Hiromi Iwasaki, Hirokazu Miki, Itaru Matsumura, Yasushi Onishi, Koji Izutsu, Masahiro Kizaki, Anupkumar George, Hillary Blacklock, David Simpson, Anders Waage, Olga Samoilova, Evgeniy Nikitin, Tatiana Chagorova, Andrew McDonald, Moosa Patel, Albert Oriol Rocafiguera, Jesus San Miguel Izquierdo, Maria Mateos, Matthew Streetly, Peter Forsyth, Graham Jackson, Stephen Jenkins, Robert Rifkin, Habte Yimer, Robert McCroskey, Danko Martincic, Stefano Tarantolo, Sarah Larson, Yacoub Faroun, Jennifer Vaughn, Rachid Baz, Gene Saylors, Amarendra Neppalli, Anastasios Raptis, Henry Fung, Maxwell Janosky, Don Stevens, Morton Coleman, Dennis Costa, Scott Cross, Suzanne Fanning, Daniel Farray Berges, Thomas Harris, Ira Zackon, Djordje Atanackovic, Kelvin Lee, Ira Oliff, Wes Lee, William Bensinger, Jose Lutzky, Ari Baron, Fadi Hayek, Eli Kirschner, Neeraj Bharany, Lindsay Overton, Siva Mannem, Allyson Harroff, Sharad Jain, Tammy Roque, Kristi McIntyre, Christopher K Yasencha, William Houck

Publikováno v: Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to improve treatment efficacy. KEYNOTE-18

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9587f7fc06343c5e2bc999bbff275d45
http://hdl.handle.net/10852/77065

The Tale of a Rubbery White Clot: Poorly Differentiated Spindle Cell Sarcoma Presenting As Superior Vena Cava Syndrome.

Autor: Hlaing SS; Department of Internal Medicine, Crozer-Chester Medical Center, Upland, USA., Ugwuegbulem E; Department of Internal Medicine, St Luke's Hospital, Bethlehem, USA., Haddock K; Department of Internal Medicine, St Luke's Hospital, Bethlehem, USA., Thwe EE; Department of Internal Medicine, St Luke's Hospital, Bethlehem, USA., Faroun Y; Department of Oncology, St Luke's Hospital, Bethlehem, USA.

Publikováno v: Cureus [Cureus] 2022 May 17; Vol. 14 (5), pp. e25071. Date of Electronic Publication: 2022 May 17 (Print Publication: 2022).